Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Moderna Inc (MRNA)

Moderna Inc (MRNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,801,562
  • Shares Outstanding, K 390,734
  • Annual Sales, $ 3,236 M
  • Annual Income, $ -3,561 M
  • EBIT $ -3,463 M
  • EBITDA $ -3,369 M
  • 60-Month Beta 1.17
  • Price/Sales 7.57
  • Price/Cash Flow N/A
  • Price/Book 1.75

Options Overview Details

View History
  • Implied Volatility 80.05% (+13.10%)
  • Historical Volatility 81.02%
  • IV Percentile 84%
  • IV Rank 51.51%
  • IV High 104.55% on 04/08/25
  • IV Low 54.03% on 08/06/25
  • Expected Move (DTE 2) 2.35 (4.81%)
  • Put/Call Vol Ratio 0.49
  • Today's Volume 150,163
  • Volume Avg (30-Day) 83,064
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 785,542
  • Open Int (30-Day) 1,018,683
  • Expected Range 46.46 to 51.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -2.74
  • Number of Estimates 9
  • High Estimate -2.50
  • Low Estimate -3.10
  • Prior Year -2.50
  • Growth Rate Est. (year over year) -9.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.06 +70.54%
on 12/31/25
49.65 -0.18%
on 01/21/26
+15.76 (+46.63%)
since 12/19/25
3-Month
22.28 +122.44%
on 11/21/25
49.65 -0.18%
on 01/21/26
+22.07 (+80.28%)
since 10/21/25
52-Week
22.28 +122.44%
on 11/21/25
49.65 -0.18%
on 01/21/26
+13.67 (+38.09%)
since 01/21/25

Most Recent Stories

More News
Moderna (MRNA) Shares Skyrocket, What You Need To Know

Moderna (MRNA) Shares Skyrocket, What You Need To Know

MRNA : 49.81 (+15.84%)
Moderna Pops 17%—Is There Life in MRNA, Down 90% from COVID High?

COVID-19 vaccine stock Moderna just got its biggest lift in recent memory, moving up 17%. Can MRNA stage a broader recovery, down +90% from its all-time high?

MRNA : 49.81 (+15.84%)
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following

At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510;...

MRK : 111.11 (+1.52%)
MRNA : 49.81 (+15.84%)
3 Healthcare Stocks Walking a Fine Line

3 Healthcare Stocks Walking a Fine Line

A : 139.77 (+2.90%)
STAA : 20.61 (-1.72%)
MRNA : 49.81 (+15.84%)
Moderna's Q4 2025 Earnings: What to Expect

Moderna will release its fourth-quarter earnings soon, and analysts anticipate a low double-digit loss decline.

XLV : 158.26 (+1.84%)
$SPX : 6,875.62 (+1.16%)
MRNA : 49.81 (+15.84%)
Wall Street slumps as bank and tech stocks fall

Losses for several banks and Big Tech stocks pulled U.S. indexes lower, even though the majority of stocks on Wall Street rose

NVDA : 183.18 (+2.87%)
AAPL : 247.65 (+0.39%)
C : 113.86 (+0.94%)
AVGO : 328.80 (-1.14%)
BAC : 52.07 (-0.06%)
CVX : 166.73 (+0.87%)
COP : 97.15 (+1.71%)
JPM : 302.04 (-0.23%)
$SPX : 6,875.62 (+1.16%)
$IUXX : 25,326.58 (+1.36%)
WFC : 86.12 (-0.62%)
XOM : 133.61 (+2.41%)
Stock Index Futures Slip With Focus on U.S. Retail Sales and PPI Data, More Big Bank Earnings on Tap

March S&P 500 E-Mini futures (ESH26) are down -0.44%, and March Nasdaq 100 E-Mini futures (NQH26) are down -0.66% this morning as investors trim risk ahead of a slew of U.S. economic data, including the...

NFLX : 85.36 (-2.18%)
C : 113.86 (+0.94%)
BAC : 52.07 (-0.06%)
SMCI : 32.25 (+2.67%)
RIVN : 16.47 (+1.92%)
ESH26 : 6,913.75 (+1.23%)
MA : 527.57 (-0.78%)
WFC : 86.12 (-0.62%)
FTNT : 75.75 (+0.38%)
V : 325.28 (-0.17%)
NQH26 : 25,501.00 (+1.48%)
ADBE : 294.22 (+1.33%)
Wall Street pulls back from its records as JPMorgan Chase and Delta kick off earnings season

Wall Street pulled back from its records following a mixed start to the latest profit reporting season for big U.S. companies

SYF : 77.13 (+1.38%)
GOOGL : 328.38 (+1.98%)
AAPL : 247.65 (+0.39%)
$SPX : 6,875.62 (+1.16%)
JPM : 302.04 (-0.23%)
CAH : 208.47 (-0.90%)
$IUXX : 25,326.58 (+1.36%)
AXP : 359.61 (+2.11%)
$DOWI : 49,077.23 (+1.21%)
CME : 279.07 (-0.30%)
CMG : 40.72 (+4.41%)
MRNA : 49.81 (+15.84%)
Stocks Fall on Weakness in Software and Credit Card Companies

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.19%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.80%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.18%. March E-mini...

GOOGL : 328.38 (+1.98%)
INTU : 524.92 (-0.76%)
JPM : 302.04 (-0.23%)
$IUXX : 25,326.58 (+1.36%)
ZNH26 : 111-210 (+0.21%)
MSFT : 444.11 (-2.29%)
ESH26 : 6,913.75 (+1.23%)
MA : 527.57 (-0.78%)
V : 325.28 (-0.17%)
AMD : 249.67 (+7.65%)
$DOWI : 49,077.23 (+1.21%)
CMG : 40.72 (+4.41%)
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings Call

MRNA : 49.81 (+15.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 80%. The market has entered extreme overbought territory.

See More Share

Business Summary

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency...

See More

Key Turning Points

3rd Resistance Point 46.13
2nd Resistance Point 44.59
1st Resistance Point 43.79
Last Price 49.81
1st Support Level 41.45
2nd Support Level 39.91
3rd Support Level 39.11

See More

Last Price 49.81
52-Week High 49.65
Fibonacci 61.8% 39.19
Fibonacci 50% 35.97
Fibonacci 38.2% 32.74
52-Week Low 22.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar